Clinical Trials Sponsored by Corcept Therapeutics

Total 6367 results

Corcept Therapeutics

Recruiting

A Phase 2b, Study Evaluating Miricorilant in Adult Patients With Nonalcoholic Steatohepatitis/Metabolic Dysfunction-Associated Steatohepatitis (MONARCH)

Nonalcoholic Steatohepatitis (NASH) | Metabolic Dysfunction-associated Steatohepatitis (MASH)

United States, Puerto Rico
Corcept Therapeutics

Recruiting

Dazucorilant in Patients With Amyotrophic Lateral Sclerosis (DAZALS)

Amyotrophic Lateral Sclerosis

Netherlands, Poland, Belgium, France, Spain, United Kingdom, Germany, Ireland, United States, Canada
Corcept Therapeutics

Recruiting

Efficacy and Safety of Relacorilant in Patients With Cortisol-Secreting Adrenal Adenomas (GRADIENT)

Hypercortisolism

United States, Austria, Bulgaria, Germany, Israel, Italy, Poland, Romania, Spain
Corcept Therapeutics

Terminated

Study of Relacorilant in Combination With Nab-Paclitaxel in Patients With Metastatic Pancreatic Ductal Adenocarcinoma (RELIANT)

Metastatic Pancreatic Ductal Adenocarcinoma

United States
Corcept Therapeutics

Completed

A Study to Evaluate the Pharmacokinetics of the Current Capsule Formulation of CORT125134 in Healthy Subjects

Healthy

United States
Corcept Therapeutics

Completed

A Study to Evaluate the Effect of Food on the Oral Bioavailability of Relacorilant in Healthy Subjects

Healthy

United States
Corcept Therapeutics

Completed

Retrospective Chart Review Study of Korlym for the Treatment of ACTH Independent Cushing's Syndrome (RE-KLAIM)

Cushing's Syndrome
Corcept Therapeutics

Terminated

Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Miricorilant in Participants With Presumed Nonalcoholic Steatohepatitis (NASH)

Nonalcoholic Steatohepatitis (NASH)

United States
Corcept Therapeutics

Active, not recruiting

Study of Relacorilant in Combination With Nab-Paclitaxel for Patients With Recurrent Platinum-Resistant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Recurrent Fallopian Tube Carcinoma | Recurrent Primary Peritoneal Carcinoma | Recurrent Ovarian Cancer

United States, Belgium, Canada, Italy, Spain
Corcept Therapeutics

Completed

A 4-week Study of Mifepristone in the Prevention of Risperidone-induced Weight Gain in Healthy Male Volunteers

Healthy

India
Corcept Therapeutics

Completed

Study to Evaluate CORT125134 in Participants With Cushing's Syndrome

Cushing's Syndrome

Netherlands, United States, Hungary, Italy, United Kingdom
Corcept Therapeutics

Completed

CORT125134 Single Ascending Dose (SAD) and Multiple Ascending Dose (MAD)

Healthy

United Kingdom
Corcept Therapeutics

Completed

First-in-human Study in Healthy Subjects

Healthy

United Kingdom
Corcept Therapeutics

Completed

Mass Balance Recovery and Metabolite Profile of CORT125281 in Healthy Male Participants

Healthy

United Kingdom
Corcept Therapeutics

Completed

A Study to Determine the Relative Bioavailability of Two New Relacorilant Capsule Variants

Healthy

United States
Corcept Therapeutics

Completed

Study in Healthy Subjects to Determine the Effect of Relacorilant on Exposure to Probe Substrates for Cytochrome P450s

Healthy

United States
Corcept Therapeutics

Completed

Mifepristone Drug-Drug Interaction Study With CYP3A Inhibitor

Healthy | Drug Interaction Potentiation

United States
Corcept Therapeutics

Completed

A United States Extension Study of Corlux for Recurrent Psychotic Symptoms in Psychotic Major Depression

Depressive Disorder, Major

United States
Corcept Therapeutics

Recruiting

Study to Determine the Prevalence of Hypercortisolism in Patients With Type 2 Diabetes and Treatment With Korlym® (Mifepristone) (CATALYST)

Diabetes Mellitus, Type 2 | Hypercortisolism

United States
Corcept Therapeutics

Recruiting

Study to Evaluate the Effects of Hepatic Impairment on the Pharmacokinetics of Miricorilant

Non-alcoholic Steatohepatitis (NASH)

United States
Corcept Therapeutics

Recruiting

A Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Miricorilant in Patients With Presumed Nonalcoholic Steatohepatitis (NASH)

Nonalcoholic Steatohepatitis (NASH)

United States
Corcept Therapeutics

Completed

Study of Relacorilant in Combination With Pembrolizumab for Patients With Adrenocortical Carcinoma Which Produces Too Much Stress Hormone (Cortisol)

Adrenocortical Carcinoma

United States
Corcept Therapeutics

Completed

A Study to Evaluate the Effects of Hepatic Impairment on the Pharmacokinetics of Relacorilant

Hepatic Impairment

United States
Corcept Therapeutics

Completed

Study to Evaluate CORT125281 in Combination With Enzalutamide in Patients With mCRPC

Metastatic Castration-Resistant Prostate Cancer

United States, United Kingdom
Corcept Therapeutics

Completed

Study to Evaluate the Effects of a Cytochrome P450 2C19 Inhibitor on the Pharmacokinetics of Miricorilant

Non-alcoholic Steatohepatitis (NASH) | Antipsychotic Induced Weight Gain

United States
Corcept Therapeutics

Completed

Effect of Relacorilant on the Pharmacokinetics of the Sensitive P-glycoprotein Substrate Dabigatran Etexilate in Healthy Participants

Neoplasms | Cushing Syndrome

United States
Corcept Therapeutics

Completed

Study to Evaluate Relacorilant (CORT125134) in Combination With Nab-paclitaxel in Participants With Solid Tumors

Solid Tumors

United States
Corcept Therapeutics

Completed

T/QT Study to Investigate the Effect of Relacorilant on Cardiac Repolarization in Healthy Volunteers

Healthy

United States
Corcept Therapeutics

Completed

The Effect of CORT118335 on Olanzapine-Induced Weight Gain

Antipsychotic-induced Weight Gain

United Kingdom
Corcept Therapeutics

Terminated

Retrospective Chart Review Study of Pediatric Patients Treated With Korlym for Cushing Syndrome

Cushing Syndrome | Hypercortisolism

United States
Corcept Therapeutics

Completed

Biomarker Expression in Patients With ACTH-Dependent Cushing's Syndrome Before and After Surgery

Cushing's Syndrome

United States
Corcept Therapeutics

Completed

CORT125281 Single Ascending Dose (SAD) and Multiple Ascending Dose (MAD)

Healthy

United Kingdom
Corcept Therapeutics

Terminated

A Study of Mifepristone vs. Placebo in the Treatment of Patients With Major Depression With Psychotic Features

Psychosis | Psychotic Depression | Severe Major Depression With Psychotic Features

United States
Corcept Therapeutics

Terminated

A Study to Confirm Recurrent or Persistent Cushing's Syndrome in Patients With Signs or Symptoms of Hypercortisolemia

Cushing's Syndrome

United States
Corcept Therapeutics

Completed

An Extension Study of CORLUX in the Treatment of Endogenous Cushing's Syndrome

Cushing's Syndrome

United States
Corcept Therapeutics

Completed

A Study of the Efficacy and Safety of CORLUX in the Treatment of Endogenous Cushing's Syndrome (SEISMIC)

Cushing's Syndrome

United States
Corcept Therapeutics

Completed

An International Extension Study of Corlux for Recurrent Psychotic Symptoms in Psychotic Major Depression

Psychotic Disorders | Major Depressive Disorder

Bulgaria, Croatia, Romania, Serbia
Corcept Therapeutics

Completed

A United States Study of Corlux for Psychotic Symptoms in Psychotic Major Depression

Psychotic Disorders | Major Depressive Disorder

United States
Corcept Therapeutics

Completed

An International Study of the Safety and Tolerability of Corlux for Psychotic Symptoms in Psychotic Major Depression

Major Depressive Disorder

Bulgaria, Croatia, Romania, Former Serbia and Montenegro
Corcept Therapeutics

Enrolling by invitation

Extension Study to Evaluate the Safety of Long-Term Use of Relacorilant in Patients With Cushing Syndrome

Cushing Syndrome

United States, Austria, Bulgaria, Germany, Israel, Italy, Netherlands, Romania, Spain, Poland, Canada
Corcept Therapeutics

Active, not recruiting

A Study of the Efficacy and Safety of Relacorilant in Patients With Endogenous Cushing Syndrome (GRACE)

Cushing Syndrome

United States, Austria, Bulgaria, Canada, Germany, Israel, Italy, Netherlands, Poland, Romania, Spain
Corcept Therapeutics

Completed

A Study to Evaluate the Pharmacokinetics of the CORT125134 Phase 2 Formulation in Healthy Male Subjects

Healthy

United States
Corcept Therapeutics

Active, not recruiting

A Sub Study of the Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Miricorilant in Patients With Presumed Nonalcoholic Steatohepatitis (NASH)

Nonalcoholic Steatohepatitis (NASH)

United States
Corcept Therapeutics

Completed

Single and Multiple Ascending Dose Study of CORT125236 in Healthy Participants

Healthy

United Kingdom
Corcept Therapeutics

Completed

Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Miricorilant in Obese Adult Patients With Schizophrenia While Taking Antipsychotic Medications (GRATITUDE II)

Antipsychotic-induced Weight Gain (AIWG)

United States
Corcept Therapeutics

Completed

This Phase 2, Double Blind, Placebo-controlled, Randomized Study is to Assess the Safety and Efficacy of Miricorilant in Obese Adult With Schizophrenia or Bipolar Disorder Treated With Antipsychotic Medications.

Antipsychotic-induced Weight Gain (AIWG)

United States
Corcept Therapeutics

Completed

Single and Multiple Ascending Dose Study of CORT125329 in Healthy Participants

Healthy

United Kingdom
Corcept Therapeutics

Completed

Single and Multiple Ascending Dose Study of CORT113176 in Healthy Participants

Healthy Adults

United Kingdom
Corcept Therapeutics

Completed

Single Dose Absorption, Distribution, Metabolism, and Excretion Study of [14C]-CORT113176 in Healthy Male Participants

Healthy

United Kingdom
Corcept Therapeutics

Completed

Safety, Tolerability, and Pharmacokinetic Study of CORT113176 in Healthy Participants

Healthy Adults

Netherlands

3

Subscribe